Get the Stockscreener App
3.78
9.88%
0.34
Genelux Corp stock is traded at $3.78, with a volume of 141.72K.
It is up +9.88% in the last 24 hours and up +14.55% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$3.44
Open:
$3.47
24h Volume:
141.72K
Relative Volume:
1.16
Market Cap:
$142.78M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-3.9789
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
+6.18%
1M Performance:
+14.55%
6M Performance:
-21.41%
1Y Performance:
+71.82%
1-Day Range:
$3.44
$3.79
1-Week Range:
$3.26
$3.79
52-Week Range:
$1.95
$5.885
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.78 | 133.72M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Has Genelux Corporation found a price floor2025 Buyback Activity & Free Long-Term Investment Growth Plans - Newser
Applying Wyckoff theory to Genelux Corporation stockWeekly Profit Recap & Fast Moving Stock Trade Plans - Newser
Is now a turning point for Genelux CorporationEarnings Overview Summary & Low Risk High Reward Ideas - Newser
What recovery options are there for Genelux CorporationLong Setup & Fast Momentum Entry Tips - Newser
Published on: 2025-08-19 11:24:03 - 선데이타임즈
Why Genelux Corporation stock attracts strong analyst attentionDollar Strength & Weekly Chart Analysis and Trade Guides - classian.co.kr
Genelux Corporation stock prediction for this weekLayoff News & Verified Momentum Stock Alerts - Newser
Can trapped investors hope for a rebound in Genelux CorporationMarket Volume Report & Long-Term Investment Growth Plans - Newser
How sentiment analysis helps forecast Genelux CorporationQuarterly Trade Review & Safe Capital Investment Plans - Newser
Heatmap analysis for Genelux Corporation and competitorsQuarterly Trade Review & Community Consensus Trade Alerts - Newser
Is a relief rally coming for Genelux Corporation holders2025 Earnings Impact & Weekly Market Pulse Updates - Newser
Genelux Corporation stock trend forecastQuarterly Market Review & Community Consensus Trade Signals - Newser
Brookline Capital Management Estimates Genelux Q3 Earnings - Defense World
Genelux Corporation stock daily chart insightsMarket Weekly Review & Weekly High Return Forecasts - Newser
Using AI based signals to follow Genelux CorporationQuarterly Growth Report & Detailed Earnings Play Alerts - Newser
News impact scoring models applied to Genelux CorporationPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - Newser
What are the risks of holding Genelux CorporationOil Prices & AI Powered Market Trend Analysis - mustnews.co.kr
Building trade automation scripts for Genelux CorporationJuly 2025 Institutional & Verified Trade Idea Suggestions - Newser
Genelux Corporation Stock Support and Resistance Levels You Should KnowJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser
Technical analysis overview for Genelux Corporation stockWeekly Trade Report & Community Shared Stock Ideas - Newser
How Efficient Is Genelux Corporation at Controlling Operating Costs [July 2025 Analyst Calls]Smart Investment Allocation Tips - Newser
Genelux Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating - TipRanks
What to do if you’re stuck in Genelux CorporationFree Community Entry Consensus Trade Ideas - Newser
Advanced analytics toolkit walkthrough for Genelux CorporationWeekly Gain Forecast with Momentum Indicators - Newser
How to escape a deep drawdown in Genelux CorporationIntraday Signal Forecast for Fast Traders - Newser
Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position - TipRanks
Genelux Corp.'s Olvi-Vec: A Promising Oncology Treatment with a Buy Rating - AInvest
Genelux Corp expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments - TipRanks
Genelux reports Q2 EPS (20c), consensus (22c) - TipRanks
Genelux Q2 Earnings Exceed Expectations with $0.20 GAAP EPS and $28.1M in Cash and Investments - AInvest
Genelux Q2 Earnings: Phase 3 Ovarian Cancer Trial On Track, 71% Success in Lung Cancer | GNLX Stock News - Stock Titan
Developing predictive dashboards with Genelux Corporation dataFree Daily Top Performing Stock Insights - Newser
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genelux Corp Stock (GNLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zindrick Thomas | President and CEO |
May 12 '25 |
Sale |
2.92 |
10,764 |
31,431 |
191,447 |
| Yu Yong | VP, Clinical Trial Operations |
May 12 '25 |
Sale |
2.92 |
5,579 |
16,291 |
47,640 |
| Cappello Joseph | VP, Pharmaceutical Development |
May 12 '25 |
Sale |
2.92 |
4,737 |
13,832 |
52,266 |
| Smalling Ralph | Head of Regulatory |
May 12 '25 |
Sale |
2.92 |
1,259 |
3,676 |
34,760 |
| Tyree James L | Director |
Dec 30 '24 |
Sale |
2.46 |
3,460 |
8,512 |
45,791 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):